CD19/IP-10 antibodies (Medarex)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCD19/IP-10 antibodies (Medarex)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsC-X-C motif chemokine ligand 10 antagonists

TargetsC-X-C motif chemokine ligand 10B-lymphocyte antigen CD19

Therapy Area/IndicationsInflammation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMedarex Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesMedarex Inc

Active IndicationsN/A

Inactive IndicationsInflammation

ATC CodeN/A